押注“停药不反弹”！医药巨头安进的减肥药新战略

华尔街见闻03-25

火热的减肥药赛道，又迎来了新的竞争者。据报道，美国制药巨头安进正在尝试一种全新的减肥药，作用机理与诺和诺德和礼来的产品存在差异，可以令患者即使停药，体重也不会反弹。安进正在测试的药物名为MariTide，与诺和诺德的Wegovy、礼来的Zepbound一样，能够激活胃肠激素受体GLP-1来抑制食欲，而且也是一种注射减肥药。 MariTide可以阻断另一种激素受体GIP，而不是像Zepbound...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422593557?lang=zh_CN&edition=full","thumbnail":"https://wpimg-wscn.awtmt.com/b4190284-a744-4e30-933d-b6d62db254d7.jpeg","is_english":false,"pubTime":"2024-03-25 14:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422593557","market":"hk","top_or_hot":-1,"title":"押注“停药不反弹”！医药巨头安进的减肥药新战略","media":"华尔街见闻","content":"<div>\n<p>火热的减肥药赛道，又迎来了新的竞争者。\n据报道，美国制药巨头安进正在尝试一种全新的减肥药，作用机理与诺和诺德和礼来的产品存在差异，可以令患者即使停药，体重也不会反弹。\n安进正在测试的药物名为MariTide，与诺和诺德的Wegovy、礼来的Zepbound一样，能够激活胃肠激素受体GLP-1来抑制食欲，而且也是一种注射减肥药。\nMariTide可以阻断另一种激素受体GIP，而不是像Zepbound...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3711219\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>押注“停药不反弹”！医药巨头安进的减肥药新战略</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n押注“停药不反弹”！医药巨头安进的减肥药新战略\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-25 14:24 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3711219><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>火热的减肥药赛道，又迎来了新的竞争者。\n据报道，美国制药巨头安进正在尝试一种全新的减肥药，作用机理与诺和诺德和礼来的产品存在差异，可以令患者即使停药，体重也不会反弹。\n安进正在测试的药物名为MariTide，与诺和诺德的Wegovy、礼来的Zepbound一样，能够激活胃肠激素受体GLP-1来抑制食欲，而且也是一种注射减肥药。\nMariTide可以阻断另一种激素受体GIP，而不是像Zepbound...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3711219\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://wallstreetcn.com/articles/3711219","article_id":"2422593557","we_media_id":null,"thumbnails":["https://wpimg-wscn.awtmt.com/b4190284-a744-4e30-933d-b6d62db254d7.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422593557","pubTimestamp":1711347841,"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"减肥药“双雄”会变成“三巨头”吗？","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","BK4139":"生物科技","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4566":"资本集团","AMGN":"安进","09939":"开拓药业-B","BK4588":"碎股","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK1161":"生物科技","BK4581":"高盛持仓","LU0058720904.USD":"联博国际健康护理基金A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2"},"translate_title":"Bet \"Stop taking drugs and don't rebound\"! The new strategy of diet pills of pharmaceutical giant Amgen","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"09939":1},"content_text":"火热的减肥药赛道，又迎来了新的竞争者。\n据报道，美国制药巨头安进正在尝试一种全新的减肥药，作用机理与诺和诺德和礼来的产品存在差异，可以令患者即使停药，体重也不会反弹。\n安进正在测试的药物名为MariTide，与诺和诺德的Wegovy、礼来的Zepbound一样，能够激活胃肠激素受体GLP-1来抑制食欲，而且也是一种注射减肥药。\nMariTide可以阻断另一种激素受体GIP，而不是像Zepbound那样激活它。基因研究表明，阻断GIP受体与较低的体脂和体重相关。\n一项小规模的早期临床试验显示，服用安进最高剂量420毫克的病人在12周内平均减重14.5%。与目前上市药物形成对比的是，MariTide似乎能帮助患者在停药后维持较长时间的减重效果。\n另一个与众不同的地方是，MariTide的给药频率可能比现有药物更低。目前的Wegovy和Zepbound需要每周注射一次，而MariTide则可每月甚至更长时间再注射一次。这主要得益于MariTide所含的单克隆抗体成分，使药物能在体内持续较长时间。\n未来，给药频率较低或许能成为MariTide的一大卖点，因为很多患者都不希望频繁注射。不过，最终病人是否选择MariTide，还取决于其减重疗效和副作用是否能与现有产品相当。\n今年晚些时候，安进将公布正在进行的两期临床试验数据，届时公众将更清楚地了解MariTide在肥胖症药物市场中的竞争前景。分析师认为，这些试验数据将解答一些关键问题，包括不同剂量下病人的耐受性等。风险提示及免责条款\n\n            市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422593557"}